Fong Wei Chern Gavin, Kaung Htet Hla Win, Lopes Rhea, Kanji Alpa, Ravenscroft Jane, Tang Ting Seng, Flohr Carsten
Centre of Evidence Based Dermatology, School of Medicine, University of Nottingham, Nottingham, UK.
Department of Dermatology, Nottingham University Hospitals NHS Trust, Nottingham, UK.
Pediatr Dermatol. 2025 Mar-Apr;42(2):358-363. doi: 10.1111/pde.15761. Epub 2024 Oct 3.
Children with severe atopic dermatitis (AD), refractory to conventional systemic treatment as well as single-agent biologic and Janus kinase inhibitor (JAKi) such as abrocitinib, currently face a lack of treatment options. In response to this clinical conundrum, we present three cases of severe and refractory pediatric AD successfully managed with combined dupilumab and abrocitinib. These children had exhausted all conventional treatments and had undergone treatment with both dupilumab and abrocitinib individually, as well as dupilumab in conjunction with methotrexate. It was only when the combination of dupilumab and abrocitinib was introduced that they finally achieved noticeable and sustained improvements in disease control.
患有重度特应性皮炎（AD）的儿童，对传统全身治疗以及单药生物制剂和如阿布昔替尼等Janus激酶抑制剂（JAKi）治疗无效，目前面临治疗选择匮乏的问题。针对这一临床难题，我们报告了3例重度难治性儿童AD患者，通过度普利尤单抗和阿布昔替尼联合治疗成功得到控制。这些儿童用尽了所有传统治疗方法，并且分别接受过度普利尤单抗、阿布昔替尼治疗，以及度普利尤单抗联合甲氨蝶呤治疗。只有在采用度普利尤单抗和阿布昔替尼联合治疗后，他们的疾病控制才最终取得了显著且持续的改善。
